- Home
- IPA
as 05-09-2025 4:00pm EST
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 20.6M | IPO Year: | 2017 |
| Target Price: | $4.00 | AVG Volume (30 days): | 407.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.27 - $1.36 | Next Earning Date: | 03-28-2025 |
| Revenue: | $16,581,105 | Revenue Growth: | 1.34% |
| Revenue Growth (this year): | 4.67% | Revenue Growth (next year): | 14.15% |
Latest ImmunoPrecise Antibodies Ltd. News
IPA Breaking Stock News: Dive into IPA Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
Simply Wall St.
a month ago
ImmunoPrecise Antibodies Third Quarter 2025 Earnings: CA$0.66 loss per share (vs CA$0.11 loss in 3Q 2024)
Business Wire
a month ago
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
Simply Wall St.
2 months ago
Positive Signs As Multiple Insiders Buy ImmunoPrecise Antibodies Stock
Business Wire
2 months ago
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
Business Wire
2 months ago
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
Business Wire
2 months ago
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
Business Wire
2 months ago
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
Compare IPA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPA ImmunoPrecise Antibodies Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.